Sonoma Pharmaceuticals, Inc.

SNOA Healthcare Drug Manufacturers Specialty & Generic

Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025. In the quarter to June 2026, revenue grew 59.6%, EPS grew 88.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.

1.13 0.02 −1.74%
Market cap
$5.5M
P/E
0.0×
Fwd P/E
−2.0×
Dividend yield
—
F-score
3/9
Altman Z
−18.52
Beneish M
−1.69
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(76.14%) (81.19%) (84.60%) (42.52%)
Piotroski F-Score
4 4 3 5
ROA
(25.26%) (24.70%) (22.96%) (13.85%)
ROIC
(259.23%) (198.48%) (220.99%) (69.96%)
Return on Tangible Assets
(41.11%) (40.89%) (41.90%) (20.38%)
Average Days of Receivables
58.25 49.06 47.23 52.98
Free Cash Flow per Share
(1.42) (2.17) (2.45) (0.69)
Free Cash Flow
(2.34) (3.72) (4.12) (2.65)
Capital Expenditures
(0.16) (0.21) (0.19) (0.09)
Other line items
Cash ROIC
(34.37%) (62.06%) (75.08%) (22.25%)
Accounts Receivable Turnover
5.78 7.40 8.21 7.58
Accounts Payable Turnover
9.71 7.21 8.42 6.32
Inventory Turnover
3.26 3.20 3.69 3.53
Average Days of Payables
48.55 54.82 57.94 59.72
Days of Inventory on Hand
125.67 123.32 110.01 103.19
Tax Rate
0.02 (0.02) (0.07) 0.00
Research and Development Expense of Revenue
11.85% 12.06% 11.63% 10.37%
Selling, General and Administrative Expense of Revenue
44.25% 41.71% 38.94% 34.95%
Share Based Compensation of Revenue
1.17% 1.18% 1.31% 1.17%
Operating CF/Net income
0.63 1.04 1.24 1.13
Depreciation/Fixed assets
0.48 0.44 0.45 0.47
Capex/Depreciation
(1.21) (1.53) (1.38) (0.65)
Revenue per Share
10.29 10.35 11.60 5.70
Operating CF per Share
(1.32) (2.05) (2.34) (0.67)
Capex per Share
(0.10) (0.12) (0.11) (0.02)
Capex to Sales
0.01 0.01 0.01 0.00

Fold the line items

Columns are period end dates